In this study, we hypothesized that the combination of VEGF-A inhibition and HIF-1α inhibition would attenuate tumor vasculature and enhance the effects of hypoxia-activated chemotherapy on sarcoma stem-like cells. This evidence concerns the gene HIF1A and neoplasm.